FLT3 and acute lymphoblastic leukemia: Overall, this study showed that more than 60% of adult ETP-ALL patients are characterized by a least a single mutation in DNMT3A, FLT3, or NOTCH1 that could guide therapeutic choices in this high-risk subgroup.